TCI GENE Inc. (6879) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of TCI GENE Inc. TWD 26.16, price TWD 35.50, upside -26.3%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch TCI GENE Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 32.60 TWD – 41.00 TWD · fair‑value band 25.76 TWD – 33.12 TWD · the 35.50 TWD price screens above the 26.16 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Follow TCI GENE in your weekly email
Every Wednesday you see whether TCI GENE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments.
Show more
TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-derived mesenchymal stem cells, natural killer immune cells, and immune cell storage programs. In addition, the company manufactures and sells testing reagents, health food, and beauty products; and health and nutritional supplements. TCI GENE Inc. was founded in 2011 and is based in Taipei, Taiwan.
Stock analysis
TCI GENE Inc. (6879) currently trades at 35.50 TWD, while our model-based Fair Value estimate is 26.16 TWD, implying the stock looks roughly 35.7% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 49.33 TWD per share, and 9 of the 24 models we run sit above the 35.50 TWD price.
Bear case: the Earnings-Based group reads lowest at 12.74 TWD, and 15 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 25.76 TWD (bear) to 33.12 TWD (bull), the price of 35.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
TCI GENE Inc. reported revenue of 274M TWD in FY2025 versus 432M TWD in FY2021, a compound −10.8%/yr. Reported net income was 40.6M TWD in FY2025, compounding −18.6%/yr from FY2021.
Key figures
Market cap 939M TWD (≈ $29.5M) · P/E ratio 18.7 · P/S ratio 2.77 · EPS (TTM) 1.90 TWD · Dividend yield 5.6% · Net margin 14.8% · Return on equity 5.6% · Return on assets (EBIT) 7.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −26%, 6879 screens richer than that median.
Fair Value models
Bear 25.76 TWDFair Value 26.16 TWDBull 33.12 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.40 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.6%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.2%
Dividend (yield on the price)5.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 7%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−18.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −19.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−26% · Above median
Profitability
Return on equity (TTM)6% · Above median
Return on assets2% · Above median
Net margin (TTM)20% · Top 25%
Operating margin (TTM)15% · Above median
Growth and dividend
Revenue growth−16% · Bottom 25%
Dividend yield (TTM)5.6% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)18.7× · Cheaper than median
P/B1.05× · Cheaper than median
P/S (TTM)3.74× · Cheaper than median
P/FCF0.2× · Cheapest 25%
EV/EBITDA20.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)22· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)100· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TCI GENE Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6879
Frequently asked questions
Is TCI GENE Inc. (6879) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 26.16 TWD versus a price of 35.50 TWD, about −26% upside (overvalued).
What is the fair value of 6879?
Our model-based fair value for TCI GENE Inc. is 26.16 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 35.50 TWD.
What is the quality score of 6879?
TCI GENE Inc. has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TCI GENE Inc. (6879)?
Our model-based price target is the fair value of 26.16 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 25.76 TWD, optimistic scenario 33.12 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TCI GENE Inc. stock forecast for 2026?
Our models put fair value at 26.16 TWD, about −26% upside versus a price of 35.50 TWD (overvalued). Cautious scenario 25.76 TWD, optimistic scenario 33.12 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TCI GENE Inc. (6879)?
TCI GENE Inc. reported trailing-twelve-month revenue of about 251M TWD (latest available figure, as of Sep 24, 2026).
Does TCI GENE Inc. pay a dividend?
TCI GENE Inc. currently shows a dividend yield of about 5.63% relative to its recent price (as of Sep 24, 2026).
What growth is priced into TCI GENE Inc. (6879)?
For today's price to be fair in a discounted-cash-flow model, TCI GENE Inc. would have to grow free cash flow by -18.5 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -10.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6879 use?
Our models discount TCI GENE Inc. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.27, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TCI GENE Inc. that is -18.5 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has TCI GENE Inc. (6879) delivered so far?
Over the past 4 years revenue at TCI GENE Inc. grew -10.8 % a year. The price currently implies -18.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TCI GENE Inc. (6879) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into TCI GENE Inc. (-18.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TCI GENE Inc. (6879)?
The free-cash-flow yield on the price is 16.07 %: that much free cash flow TCI GENE Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TCI GENE Inc. (6879)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TCI GENE Inc. it is 26.16 TWD per share (as of Sep 24, 2026), against a price of 35.50 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is TCI GENE Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6879 trades above its calculated fair value: price 35.50 TWD, fair value 26.16 TWD, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6879?
No. The price is what the market pays today (35.50 TWD); the fair value is what the company's own numbers justify (26.16 TWD). For TCI GENE Inc. the two are 9.34 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TCI GENE Inc. worth?
The market values TCI GENE Inc. at about 939M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 35.50 TWD; our models calculate a fair value of 26.16 TWD per share.
What do the bullish and bearish scenarios say about 6879?
Our models span a range for TCI GENE Inc.: cautious scenario 25.76 TWD, base 26.16 TWD, optimistic 33.12 TWD per share (as of Sep 24, 2026, price 35.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6879?
TCI GENE Inc. trades at a price-to-earnings ratio of 18.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26.16 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 3.7, EV/EBITDA 20.4.
How solid is the balance sheet of TCI GENE Inc. (6879)?
Balance-sheet figures for TCI GENE Inc. (as of Sep 24, 2026): return on equity 5.6%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
Which stocks are comparable to TCI GENE Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TCI GENE Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 35.50 TWD, calculated fair value 26.16 TWD (−26%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6879 calculated?
We run TCI GENE Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 26.16 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. TCI GENE Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TCI GENE Inc. (6879)?
The closing price on Sep 24, 2026 was 35.50 TWD. Our model-based fair value is 26.16 TWD, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TCI GENE Inc. right now?
A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (33.12 TWD). The favourable scenario is already priced in.
Key figures of TCI GENE Inc.
How large is the market capitalisation of TCI GENE Inc. (6879)?
The market capitalisation of TCI GENE Inc. is 939M TWD (≈ $29.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TCI GENE Inc. (6879)?
The price-to-sales ratio of TCI GENE Inc. is 2.77 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TCI GENE Inc. (6879)?
Earnings per share at TCI GENE Inc. are 1.90 TWD (price ÷ EPS = P/E 18.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TCI GENE Inc. (6879)?
The dividend yield of TCI GENE Inc. is 5.6% (payout 105%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TCI GENE Inc. (6879)?
The net margin of TCI GENE Inc. is 14.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TCI GENE Inc. (6879)?
The return on equity (ROE) of TCI GENE Inc. is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TCI GENE Inc. (6879)?
On an EBIT basis the return on assets of TCI GENE Inc. is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TCI GENE Inc. (6879)?
The operating margin of TCI GENE Inc. is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TCI GENE Inc. (6879)?
Revenue at TCI GENE Inc. is growing −15.7% versus a year earlier (3y avg −13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TCI GENE Inc. (6879)?
Earnings per share at TCI GENE Inc. are growing +325% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch TCI GENE Inc. in the live analysis
One click puts TCI GENE Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
